Business
ESM - Schedule One
ESM - Schedule One.
About this update from Talisman Metals Plc
[{"type":"text","content":"\n \nRNS Number : 4975T Ovoca Gold PLC 04 July 2018 \n\nPre-Admission AnnouncementESM Schedule 1\n\n\n\n\nAnnouncement to be made by the ESM Applicant prior to admission in accordance with\nrule 2 of the ESM Rules for Companies\n\n\n\n\n\nAll Applicants must complete the following\n\n\n\n\n\nCompany name \nOvoca Gold plc, to be renamed Ovoca Bio plc\n\n\n\n\n\n\n\nCompany registered address and if different, company trading address (including postcodes)\n\n\n\n\nRegistered Office: 17 Pembroke Street Upper, Dublin 2, Ireland\n\n\n\n\nCountry of incorporation Ireland\n\n\n\n\n\n\n\nCompany website address containing all information required by rule 26 in the ESM Rules\nfor Companies\n\n\n\n\nwww.ovocagold.com, to become www.ovocabio.com on Admission \n\n\n\n\nCompany business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the ESM Rules for Companies, this should be stated\nIn recent months, Ovoca has engaged with IVIX, a Russian company developing a drug candidate for the treatment of female sexual dysfunctions. Following satisfactory progression of these discussions, the Board has today announced that Silverstar, a subsidiary of the Company, has entered into a conditional transaction to acquire up to 59.9 per cent of the participation interests (shares) in the charter capital of IVIX for a cash consideration of up to (approximately) US$6.2 million, to be satisfied from the existing cash resources of Ovoca. \n \nIVIX was incorporated in 2012 and since that time has sought to develop and subsequently commercialise a proprietary drug candidate, BP101 (known as Libicore), for the treatment of female sexual dysfunctions. To date, IVIX has completed Phase II clinical trials in Russia for Libicore. It now intends to complete the Russian Phase III clinical trial, following which it will seek approval for the marketing of Libicore in the Russian market. IVIX has also initiated discussions with the FDA for the potential approval of Libicore development dossier for the US market. \n \nThe nature of the Company's business will be transformed by the Transaction and, in order to reflect its new activities, it is proposed to change the Company's name to Ovo...